A pediatric patient with cystic fibrosis and a double-lung transplant received a genetically engineered 3-phage cocktail to treat a life-threatening antibiotic-resistant Mycobacterium abscessus infection for which all standard therapeutic options had been exhausted. Over 7 months of twice-daily intravenous infusions, as well as daily topical phage therapy, the 15-year-old patient’s surgical wound and skin lesions healed gradually and her lung and liver function improved. No adverse reactions to the treatment were reported.
Abbasi J. Patient Receives First Genetically Engineered Phage Treatment. JAMA. 2019;322(2):107. doi:10.1001/jama.2019.9394
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: